Diabetic Retinopathy: The Masqueraders By: Irene A. Barbazetto, M.D. Clinical hallmarks of DR can be associated with a variety of diseases How Baseline Assessment of AMD Lesion Type Influences Clinical Decisions and Outcomes By: Usha Chakravarthy, MD, FRCS, FRCOphth, PhD; Stuart McGimpsey, MD, FRCOphth; Clara McAvoy, MD, FRCOphth Careful diagnosis and phenotyping of neovascular AMD patients is still required in the anti-VEGF era Great Debates in RVO Therapy By: Frank Celia, Contributing Editor An anti-VEGF and steroid gain FDA sanction, but many clinical questions remain A Brave New World By: Pravin U. Dugel, MD; Ram Palanki, PharmD; Kuo Bianchini Tong, MS The retina subspecialty is in the vanguard of changes to clinical practice and reimbursement Visualization Agents for Vitreoretinal Surgery By: Andrew E. Mathis, PhD, Medical Editor Intraoperative dyes can be a useful adjunct, but what are the pros and cons? Surgeons share their insights Case Report By: Kevin K. Suk, MD; Audina M. Berrocal, MD; Timothy G. Murray, MD, MBA; Ditte Hess, CRA Intravitreal Bevacizumab in a Silicone-filled Eye Microperimetry and Pituitary Adenoma By: Federico M. Rathschuler, MD Benign tumors can present as retinal symptoms Upfront: From the Editor-in-Chief By: Jason S. Slakter, M.D. Shortcuts Subspecialty News Small study jumps the gun on CATT; Data on PDT/Lucentis combinations; Radiation as a supplement to Anti-VEGF; and more Controversies in Care By: Michael Colucciello, MD Avastin vs Lucentis for the treatment of neovascular AMD Journal Club By: Andrew E. Mathis, PhD, Medical Editor Studies to stimulate discussion and debate Coding Q & A By: Riva Lee Asbell Audit-causing issues in the retina practice Focus On By: Jack Persico, Executive Editor The InVitria injection assistant Clinical Trials Update Current Issue: July 2010
		| © Wolters Kluwer Pharma Solutions, Inc.|VisionCare Group All Rights Reserved - Terms and Conditions of Service